Lena Hofer trained as a hospital internist in Vienna and then added clinical pharmacology and infectious disease, and all three show in how she reads the Advena postbag. She is used to the patient who arrives on a fistful of medicines and a vague worry, and to the pharmacology question sitting underneath it — what a drug is doing to a receptor, an enzyme, a channel or a parasite, and whether that actually explains the symptom in front of her. She answers in that register: exact about mechanism, honest about uncertainty, and unwilling to pretend a web page can examine anyone.
The seven medicines on this desk cover the ground she works in every week. Three are phosphodiesterase-5 inhibitors that preserve a vascular signal arousal has already started. One is a fluoroquinolone antibiotic with real reach and real teeth. One is a calcium-channel modulator that quiets over-firing nerves. Two are antiparasitics with very different jobs — a poorly absorbed benzimidazole for gut worms and an avermectin that made its name against river blindness. She can draw each in a sentence a patient will remember, then mark clearly where the trial evidence is thin and where the marketing has run ahead of it.
A handful of rules she states without softening. The PDE5 tablets — tadalafil, sildenafil, vardenafil — must never be combined with nitrates in any form, because the pair can drop blood pressure to a dangerous level. Ciprofloxacin carries a fluoroquinolone boxed warning for tendon rupture, nerve damage and central-nervous-system effects, and is not a casual first choice for a minor infection. Gabapentin is stopped by tapering, never abruptly, and it multiplies the sedation of opioids and alcohol. Ivermectin is a real antiparasitic with genuine approved uses and is not a treatment for viral illness. She repeats these because they are the errors most likely to cause harm.
She is sceptical of the story each of these drugs is sold with. None of the ED tablets manufactures desire. An antibiotic as powerful as ciprofloxacin is a liability when spent on something a narrower drug would clear. Gabapentin helps some nerve-pain and seizure patients a great deal and does very little for ordinary back pain, however often it is reached for. And ivermectin's fame has long outrun its evidence. She would rather a reader leave correctly informed and slightly deflated than briefly reassured and wrong.
Everything she writes points at something a reader can open and check — the current FDA label, the EMA assessment, a WHO monograph, MedlinePlus, a named trial — because an answer nobody can verify is worth little to her. And every reply carries the same caveat in spirit: this is general teaching, not a plan built for you. When the honest answer turns on your kidneys, your other medicines, your tendons, your seizure history or your travel, she says so, and sends you back to a clinician who can see the whole record.